Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome.
Steven A. Schichman(Central Arkansas Veterans Healthcare System), David S. Viswanatha(Mayo Clinic), Tait D. Shanafelt(Mayo Clinic), Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Timothy G. Call(Mayo Clinic), Neil E. Kay(Mayo Clinic), Clive S. Zent(University of Rochester Medical Center), Weleetka Carter(Central Arkansas Veterans Healthcare System), Lori Frederick(Mayo Clinic), Annjanette Stone(Central Arkansas Veterans Healthcare System), Maria Winters(Central Arkansas Veterans Healthcare System)
Cited by 0
Related Papers
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Changes in Burnout and Satisfaction With Work-Life Integration in Physicians and the General US Working Population Between 2011 and 2017
|Mayo Clinic Proceedings|2019|903
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630